Identification of urine PLK2 as a marker of bladder tumors by proteomic analysis

World Journal of Urology

Volumn 28, Issue 1, 2010, Pages 117-122

  Tan, Lia Beng ^a,b   Chen, Kow Tong ^b   Yuan, Yu Chang ^b   Liao, Pao Chi ^b   Guo, How Ran ^b  

^a St Joseph's Hospital   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Bladder cancer biomarker; Nano HPLC ESI MS MS; PLK2; Urinary proteome

Indexed keywords

PLK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; PROTEOMICS; URINE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 75849136050     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0432-y     Document Type: Article

References (30)

1. Vlahou H, Schellhammer PF, Mendrinos S et al (2001) Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158: 1491-1502.
2. Sarosdy MF, deVere White RW, Soloway MS (1995) Results of a multicenter trial using the BTA test to monitor for and diagnosis recurrent bladder cancer. J Urol 154: 379-384.
3. Sharms S, Zipper CD, Pandrangi L (1999) Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA test. J Urol 162: 53-57.
4. Greence FL, Page DL, Fleming ID et al (eds) (2002) American Joint Committee on Cancer Staging manual, 6th edn. Springer, Philadelphia.
5. World Health Organization (1988) International histological classification of tumors, 2nd edn. World Health Organization, Geneva, 1969-1981, Springer, Berlin.
6. Tan LB, Chen KT, Tyan YC, Liao PC, Guo HR (2008) Proteomic analysis for human urinary proteins associated with arsenic intoxication. Proteomic Clin Appl 2: 1087-1098.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of protein. Anal Biochem 72: 248-254.
8. Washburn MP, Wolters DA, Yates JR (2001) Large-scale analysis of the yeast proteome by multidimensional technology. Nat Biotechnol 19: 242-247.
9. Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW (2008) The E-cadherin gene polymorphism 160C→A and cancer risk: a HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol 167: 7-14.
10. Kunzli BM, Berberat PO, Zhu ZW et al (2002) Influences of the lysosomal associated membrane proteins (Lamp-1, Lamp-2) and Mac-2 binding protein (Mac-2-BP) on the prognosis of pancreatic carcinoma. Cancer 94: 228-239.
11. Saitoh O, Wang WC, Lotan R, Fukuda M (1992) Differential glycosylation and cell surface expression of lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic potentials. J Biol Chem 267: 5700-5711.
12. Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI (2005) Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 96: 803-805.
13. Deepak AG, Chen T, Irby R et al (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94: 513-516.
14. Tolson JP, Flad T, Gnau V et al (2006) Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 6: 697-708.
15. El-Rifai W, Moskaluk CA, Abdrabbo MK et al (2002) Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62: 6823-6826.
16. Yoon SY, Lee Y, Kim JH et al (2005) Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. Biochem Biophys Res Commun 326: 7-17.
17. Wang Y, Han KJ, Pang XW et al (2002) Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol 169: 1102-1109.
18. Rudman D, Chawla RK, Wadsworth AD, Nixon DW, Schwartz M (1977) A system of cancer-related urinary glycoproteins: biochemical properties and clinical applications. Trans Assoc Am Physicians 90: 286-299.
19. Chawla RK, Lawson DH, Ahmad M, Travis J (1992) Cancer-related urinary proteinase inhibitor, EDC1: a new method for its isolation and evidence for multiple forms. J Cell Biochem 50: 227-236.
20. Syed N, Smith P, Sullivan A et al (2006) Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood 107: 250-256.
21. Ylagan LR, Scholes J, Demopoulos R (2000) CD 44: a marker of squamous differentiation in adenosquamous neoplasms. Arch Pathol Lab Med 124: 212-215.
22. Miyake H, Hara I, Kamidono S, Eto H (2004) Multifocal transitional cell carcinoma of the bladder and upper urinary tract: molecular screening of clonal origin by characterizing CD44 alternative splicing patterns. J Urol 172: 1127-1129.
23. Koochekpour S, Zhuang YJ, Beroukhim R et al (2005) Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 44: 351-364.
24. Mukoyama Y, Zhou S, Miyachi Y, Matsuyoshi N (2005) T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells. J Invest Dermatol 124: 833-838.
25. Halachmi S, Linn JF, Amiel GE, Moskovitz B, Nativ O (1998) Urine cytology, tumour markers and bladder cancer. Brit J Urol 82: 647-654.
26. Sphar CS, Davis MT, McGinley MD et al (2001) Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. I. Profiling an unfractionated tryptic digest. Proteomics 1: 93-107.
27. D'Assoro AB, Lingle L, Salisbury JL (2000) Centrosome amplification and the development of cancer. Oncogene 21: 6146-6153.
28. Malumbres M, Barbacid M (2007) Cell cycle kinases in cancer. Curr Opin Genet Dev 17: 60-65.
29. Nigg E (2000) Centrosome aberrations: cause or consequence of cancer progression? Nat Rev Cancer 2: 815-825.
30. Yamamoto Y, Matsuyama H, Kawauchi S et al (2006) Overexpression of Polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer. Oncology 70: 231-237.